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Background: The timing of infection is closely determined in controlled human malaria
infection (CHMI) studies, and as such they provide a unique opportunity to dissect
changes in immunological responses before and after a single infection. The first Kenyan
Challenge Study (KCS) (Pan African Clinical Trial Registry: PACTR20121100033272) was
performed in 2013 with the aim of establishing the CHMI model in Kenya. This study used
aseptic, cryopreserved, attenuated Plasmodium falciparum sporozoites administered by
needle and syringe (PfSPZ Challenge) and was the first to evaluate parasite dynamics
post-CHMI in individuals with varying degrees of prior exposure to malaria.
Methods: We describe detailed serological and functional immunological responses
pre- and post-CHMI for participants in the KCS and compare these with those from
malaria-naïve UK volunteers who also underwent CHMI (VAC049) (ClinicalTrials.gov
NCT01465048) using PfSPZ Challenge. We assessed antibody responses to three key
blood-stage merozoite antigens [merozoite surface protein 1 (MSP1), apical membrane
protein 1 (AMA1), and reticulocyte-binding protein homolog 5 (RH5)] and functional
activity using two candidate measures of anti-merozoite immunity; the growth inhibition
activity (GIA) assay and the antibody-dependent respiratory burst activity (ADRB) assay.
Results: Clear serological differences were observed pre- and post-CHMI by ELISA
between malaria-naïve UK volunteers in VAC049, and Kenyan volunteers who had prior
malaria exposure. Antibodies to AMA1 and schizont extract correlated with parasite
multiplication rate (PMR) post-CHMI in KCS. Serum from volunteer 110 in KCS, who
demonstrated a dramatically reduced PMR in vivo, had no in vitro GIA prior to CHMI
but the highest level of ADRB activity. A significant difference in ADRB activity was
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seen between KCS volunteers with minimal and definite prior exposure to malaria and
significant increases were seen in ADRB activity post-CHMI in Kenyan volunteers. Quinine
and atovaquone/proguanil, previously assumed to be removed by IgG purification, were
identified as likely giving rise to aberrantly high in vitro GIA results.
Conclusions: The ADRB activity assay is a promising functional assay that warrants
further investigation as a measure of prior exposure to malaria and predictor of control
of parasite growth. The CHMI model can be used to evaluate potential measures of
naturally-acquired immunity to malaria.
Keywords: malaria, challenge, falciparum, immunity, CHMI, ELISA, GIA, ADRB
INTRODUCTION
Although encouraging evidence suggests that the epidemiology
of Plasmodium falciparum malaria is changing across certain
parts of Africa (Okiro et al., 2007), the burden of disease
from malaria remains a major public health problem, with
approximately 214 million cases and 438,000 deaths worldwide
in 2015 (WHO, 2015). Despite considerable efforts, the
development of a highly effective vaccine against malaria
infection, disease, or transmission remains elusive (Halbroth and
Draper, 2015).
Controlled human malaria infection (CHMI) studies have
become a vital, routine tool to accelerate vaccine and drug
development against P. falciparum (McCarthy et al., 2011;
Sauerwein et al., 2011; Duncan and Draper, 2012; Roestenberg
et al., 2012). By infecting healthy volunteers with P. falciparum
parasites in a controlled environment, CHMI studies have been
used to deselect vaccine candidates to ensure only the most
promising move forward to evaluation in field studies (Sheehy
et al., 2013a).
Whilst routinely performed in American, European, and
Australian centers with malaria-naïve subjects, modern P.
falciparum CHMI studies have rarely been performed in malaria-
endemic regions or involved volunteers with prior exposure to
malaria (Sauerwein et al., 2011; Sheehy et al., 2013a). This has
primarily been due to the lack of access to appropriate facilities to
performmosquito-bite CHMI trials inmalaria endemic countries
(Sheehy et al., 2013a). The development of aseptic, cryopreserved
P. falciparum sporozoites (NF54 strain) for injection (PfSPZ
Challenge) by the biotechnology company Sanaria Inc., has
helped overcome this problem (Epstein, 2013; Roestenberg et al.,
2013; Sheehy et al., 2013b; Gómez-Pérez et al., 2015; Lyke et al.,
2015) and recently, CHMI studies have been undertaken in
Tanzania, Kenya andMali using PfSPZChallenge (Hodgson et al.,
2014; Shekalaghe et al., 2014).
Given the timing of infection is closely controlled in CHMI
studies, they provide the opportunity to dissect in detail changes
in immunological responses before and after a single infection. In
malaria-exposed individuals, they also provide the opportunity
to assess the effect of prior exposure to P. falciparum, and
by inference, naturally-acquired immunity (NAI) on parasite
growth dynamics.
The Kenyan Challenge Study (KCS) was the first modern
CHMI study performed in Kenya (Hodgson et al., 2014). In this
study, all 28 volunteers were successfully infected with malaria
and one participant (volunteer 110) remained undiagnosed by
thick-film microscopy 21 days post-injection of PfSPZ Challenge
(C+21). Parasite multiplication rate (PMR), a measure of the fold
change in blood-stage parasitaemia over 48 h, was calculated for
each participant and a range of PMRs were seen in diagnosed
volunteers (median 11.1, range 5.2–18), whilst volunteer 110 had
a markedly reduced PMR of 1.3.
KCS was the first CHMI study to attempt to define the degree
of prior exposure (and therefore NAI) to malaria prior to CHMI.
Whilst the enrolled volunteers were concluded to have low to
moderate NAI, the range of PMRs seen and the finding of
one individual clearly capable of controlling blood-stage parasite
growth in vivo suggested PMR as a potential measure of NAI
against which immunological assays, including functional assays,
could be assessed.
Here were describe detailed serological and functional
immunological responses for participants in KCS before and after
CHMI and compare these with those from malaria-naïve UK
volunteers who also underwent CHMI using PfSPZ Challenge (in
a previously reported clinical trial called VAC049) (Sheehy et al.,
2013b). Of the many potential blood-stage antigens, we chose
to assess antibody responses to three well-known anti-merozoite
vaccine candidates; merozoite surface protein 1 (MSP1), apical
membrane protein 1 (AMA1), and reticulocyte-binding protein
homolog 5 (RH5) (Sheehy et al., 2012b; Biswas et al., 2014;
Douglas et al., 2015; Halbroth and Draper, 2015; Payne et al.,
2016). We also chose to assess two candidate measures of anti-
merozoite immunity; the widely used growth inhibition activity
(GIA) assay, which assesses the ability of purified IgG to inhibit P.
falciparum growth in vitro in a cell-independent manner (Malkin
et al., 2005; Duncan et al., 2012), and the antibody-dependent
respiratory burst activity (ADRB) assay which assesses the ability
of antibody to opsonize merozoites and induce the release
of reactive oxygen species (ROS) from polymorphonuclear
neutrophils in vitro (Joos et al., 2010; Kapelski et al., 2014;
Llewellyn et al., 2014, 2015).
This work is the first to compare changes in key
immunological measures pre- and post-acute P. falciparum
infection in adults with varying degrees of prior exposure
to malaria. As such, these findings provide important
information on the value of immunological measures
at predicting prior exposure and therefore immunity to
P. falciparum.
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MATERIALS AND METHODS (SEE
SUPPLEMENTARY INFORMATION)
Controlled Human Malaria Infection
Studies
CHMI was undertaken by needle and syringe administration of
aseptic, un-attenuated P. falciparum sporozoites, cryopreserved
at known concentrations and stored in liquid phase liquid
nitrogen (PfSPZ Challenge) (Sheehy et al., 2013b; Hodgson et al.,
2014).
KCS was an open label, randomized pilot study with blinded
laboratory outcome assessment, evaluating PfSPZ Challenge
administered intramuscularly (IM) to 28 individuals with varying
degrees of prior exposure to P. falciparum (Figure 1) (Hodgson
et al., 2014). A dose escalation study design was applied to allow
assessment of safety prior to administration of the target dose of
125,000 sporozoites. Volunteers in KCS were grouped into those
with minimal (MinExp) or definite (DefExp) prior exposure
to malaria according to antibody responses to schizont extract
and merozoite surface protein 2 (MSP2) as previously described
(Hodgson et al., 2014, 2015). The study was conducted at the
Kenya Medical Research Institute (KEMRI) Centre for Clinical
Research, Nairobi, Kenya, and registered with the Pan African
Clinical Trial Registry (PACTR20121100033272).
VAC049 was an open label, non randomized pilot study with
blinded laboratory outcome assessment evaluating the safety and
infectivity of various doses of PfSPZ Challenge administered IM
and intradermally (ID) in 18 malaria-naïve, UK adults (Figure 1)
(Sheehy et al., 2013b). The study was conducted at the Centre
for Clinical Vaccinology and Tropical Medicine, University
of Oxford, Oxford, UK and registered with ClinicalTrials.gov
(NCT01465048).
Both studies were conducted according to the principles of the
Declaration of Helsinki and in accordance with Good Clinical
Practice (GCP). In both studies, participants were treated with
a 3-day curative course of Atovaquanone/Proguanil at C+21.
ELISAs
All ELISAs were standardized and performed according to
published protocols using serum (Miura et al., 2008; Sheehy
et al., 2012a,b; see Supplementary Information). Anti-AMA1
(full-length), anti-MSP1 (19 kDa C−terminal region, MSP119),
and anti-RH5 (full-length) ELISAs were performed at the
Jenner Institute, University of Oxford whilst the anti-schizont
ELISA was performed at KEMRI-Wellcome Trust, Centre for
Geographical Medical Research (Coast), Kilifi. Due to limited
sample volumes, antibodies to schizont extract were not assessed
for subjects enrolled in VAC049. Antibody unit = the dilution of
the sample that would give an OD of 1.0 under the given ELISA
conditions.
Growth Inhibition Activity Assay
The ability of antibodies to inhibit growth of P. falciparum 3D7
clone parasites in vitro was assessed by a standardized GIA assay
using purified IgG at 10 mg/mL as previously described (Malkin
et al., 2005). This assay was performed at the GIA Reference
Center (Laboratory of Malaria and Vector Research, NIH). The
3D7 clone was originally isolated from the NF54 parental strain
and is thus closely related to the PfSPZ Challenge inoculum.
Antibody-Dependent Respiratory Burst
Activity Assay
The ability of donor neutrophils to produce reactive oxygen
species (ROS) in the presence of test serum and P. falciparum
3D7 clone merozoites was assessed using a standardized assay at
the Jenner Institute, University of Oxford (Llewellyn et al., 2015).
100µL serum diluted 1:50 in PBS added to 50µL of isolated
human PMNs at 1 × 107 PMNs/mL was tested against 3D7
parasites (see Supplementary Information).
Parasite Growth Modeling
Sampling for qPCR to measure blood-stage parasitemia was
performed 1–2 times a day and qPCR conducted as previously
described (Sheehy et al., 2012b). Results were modeled using
simple linear regression (Douglas et al., 2013; Hodgson et al.,
2014) to estimate PMR (see Supplementary Information). PMR
is the fold change in number of parasites in the blood over one
lifecycle (48 h ). Liver to blood inoculum (LBI) is the total number
of parasites released from the liver at C+6.5.
Statistical Analysis
The study was designed to assess proof of concept and group
sizes were pragmatic rather than based on a formal sample size
calculation for any one defined endpoint; statistical analyses were
therefore primarily descriptive in nature and results interpreted
with caution. Multiple analyses to interrogate the relationship
between outcome measures were hypothesis generating and
recognized to require replication in future studies.
Results were compared between groups using the Mann-
Whitney U test, Wilcoxin matched-pairs signed rank test or
Kruskal-Wallis test as appropriate. Correlations were assessed
using Spearman’s rank correlation coefficient. Data were analyzed
using GraphPad Prism version 5.03 for Windows (GraphPad
Software Inc., USA).
RESULTS
Infectivity of CHMI Studies
In VAC049, 14 volunteers were successfully infected, with four
volunteers qPCR negative throughout follow-up (Figures S1A,C;
Sheehy et al., 2013b). In KCS, all 28 volunteers were successfully
infected as assessed by qPCR (Figures S1B,C), however, one
volunteer (110) was undiagnosed by thick film microscopy by
C+21 with a notably reduced PMR compared to the other
volunteers (Figure S2; Hodgson et al., 2014).
There was no significant difference in parasitaemia at
diagnosis (p/mL measured by qPCR) between volunteers
diagnosed in VAC049 and KCS (p = 0.213, Mann-Whitney U
test, data not shown). However, a significant difference in time
to diagnosis was seen between studies (p = 0.006, Log rank
test; Figure S1C), most likely reflecting variation in LBI due to
differences in number and route of administration of sporozoites
between studies (Figure S3, Figure 1).
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FIGURE 1 | Design of Studies. (A) VAC049 was a UK CHMI study of PfSPZ Challenge administered to malaria-naïve, UK volunteers. (B) KCS was a Kenyan
Challenge Study of PfSPZ Challenge administered to Kenyan volunteers. In each study in each group, the total dose of sporozoites was split between two injection
sites and administered as two 50µL injections, one in each deltoid. ID, intradermal; IM, intramuscular; MinExp, minimal prior exposure to malaria; DefExp, definite
prior exposure to malaria.
Analyses of Antibody Responses
Antibody responses in VAC049 to MSP119 and AMA1 in
volunteers infected with malaria were significantly induced
following a single infection (Figure S4A) and were comparable
to those reported in UK controls following mosquito-bite CHMI
(Biswas et al., 2014). Responses to RH5 were not detected in UK
adults post-CHMI, in agreement with this antigen being weakly
recognized in the context of natural malaria infection (Douglas
et al., 2011; Villasis et al., 2012; Tran et al., 2014).
Comparison of ELISA results between VAC049 and the
MinExp volunteers in KCS showed no significant differences
at baseline (C−1), consistent with this group of Kenyan
volunteers being minimally-exposed and relatively similar to
malaria-naïve UK adults (Figure S4B, Table S1). However, at
C+35, a significant difference in responses to MSP119 was seen
(Figure S4C, Table S1), and a similar trend was observed for
AMA1—consistent with some degree of previous B cell priming
(Elias et al., 2014). Again, serological responses against RH5
remained largely negative in both groups.
In KCS, a significant difference in baseline antibody responses
was seen between DefExp andMinExp volunteers for all antigens
except RH5 (Figures 2A–D). Consistent with the above, antibody
responses to all antigens (with the exception of RH5) were
significantly boosted following CHMI for both DefExp and
MinExp volunteers (Figures 2A–D) and across all volunteers
(Table 1, top row), with the DefExp group showing the highest
responses at C+35. Of note, the highest antibody responses to
MSP119 and AMA1 in KCS were still lower than those seen
following vaccination of UK adults with viral vectored vaccines
encoding these antigens (and assessed using the same ELISA
assay), but were similar to those recently reported for a cohort
of naturally-immune Kenyan adults (Sheehy et al., 2012b; Biswas
et al., 2014).
For KCS, only antibody responses at C−1 to schizont and
AMA1 showed a significant correlation to PMR (p = 0.044
and p = 0.018 respectively; Table 1). For VAC049, no antibody
responses (measured at C+35) were shown to correlate with the
number of parasites at diagnosis (Table S1), however, in KCS
schizont (C+35) andMSP119 ELISA (C−1 and C+35) associated
with parasitemia at diagnosis (Table 1). These data are similar to
those previously reported suggesting de novo anti-MSP119 serum
IgG responses post-mosquito bite CHMI in UK malaria-naïve
control volunteers associate with the duration of blood-stage
parasite exposure (Elias et al., 2014).
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FIGURE 2 | Serum IgG antibody responses for volunteers with Minimal and Definite prior exposure to malaria in KCS.(A) MSP119. (B) AMA1. (C) RH5.
(D) Schizont extract. Median values are indicated. Mann Whitney U tests and Wilcoxon matched-pairs signed rank tests as appropriate. Data from volunteer 110
highlighted in red. MinExp, minimal prior exposure to malaria; DefExp, definite prior exposure to malaria. C−1, baseline pre-CHMI. C+35 = 35 days post-CHMI.
*p < 0.05, ***p < 0.001, ****p < 0.0001.
Analyses of in vitro Growth Inhibition
Activity
GIA was assessed using purified IgG from serum of VAC049
volunteers before and after CHMI. No result was obtained for
volunteer 1224 (Group 1, successfully infected) at C−1 due
to a technical failure. A number of unexpected results were
seen. Firstly, one subject, (volunteer 1221, group 1, successfully
infected) was shown to have GIA of 99.9% at C−1 (expected
to be <20%) (Figure 3A). This volunteer was shown to have
a plasma concentration of 11 ng/mL of quinine at C−1 (see
supplementary information), confirmed by repeated testing, and
likely represented surreptitious quinine use by the volunteer
(although the volunteer denied this).
The second finding of note was that GIA increased post-
CHMI across the cohort, but most markedly in the four subjects
that were not successfully infected in VAC049 (i.e., qPCR
negative from C+6.5 until C+21) (Figure 3B). This finding
was in contrast to other studies where no GIA was induced in
malaria-naïve adults following a single CHMI (Duncan et al.,
2011; Biswas et al., 2014). A correlation was seen between GIA
at C+35 and days between start of anti-malarial therapy and
sampling at C+35. Given that uninfected subjects in VAC049
were treated at C+21, at least 3 days later than the other subjects,
they had a shorter interval between completion of their drug
therapy and sampling at C+35. It is likely therefore that the
increase in GIA seen post-CHMI is secondary to a residual effect
from Atovaquone/Proguanil (MalaroneTM), persisting despite
purification of IgG, rather than mediated by antibody induced
following a single malaria infection.
Analysis of GIA pre- and post-CHMI in KCS showed a
significant increase post-infection (p ≤ 0.0001) (Figure 4A).
No significant difference in GIA was seen between MinExp
and DefExp subjects at C−1 or C+35 (Figure 4B). Volunteer
110, who had a markedly reduced PMR in vivo post-infection
(1.3/48 h; group median 11.1), demonstrated no GIA prior to
CHMI (−0.4%) and only minimal GIA post-CHMI (27%). The
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TABLE 1 | Analyses of antibody responses and ADRB activity for KCS.
Comparison MSP119 IgG Titre AMA1 IgG Titre RH5 IgG Titre Schizont OD GIA ADRB
p r p r P r p r p r p r
C−1v C+35 <0.0001 <0.0001 0.148 <0.0001 <0.0001 <0.0001
Parasitemia at diagnosis v C−1 0.042 0.395 0.066 0.359 0.193 0.259 0.202 0.253 0.930 −0.018 0.167 0.274
Parasaemia at diagnosis v C+35 0.036 0.405 0.208 0.208 0.960 0.011 0.037 0.404 0.283 0.214 0.103 0.321
PMR v C−1 0.886 −0.029 0.018 −0.443 0.491 −0.136 0.044 -0.384 0.780 −0.337 0.192 −0.254
ADRB C+35 v C+35 0.0002 0.649 0.0001 0.658 0.111 0.308 <0.0001 0.886 0.111 0.308
n = 28 for all analyses. Correlations were performed using Spearman rank test. Comparisons were performed using Wilcoxon matched-pairs signed rank or Mann Whitney U tests as
appropriate (top row only). These analyses were hypothesis driven and key findings require replication in future studies. Results in bold are statistically significant.
FIGURE 3 | VAC049 GIA data. (A) Pre- and post–CHMI. Wilcoxon matched-pairs signed rank test. Individual data and median are shown. (B) Correlation between
GIA at C+35 and days between start of anti-malarial therapy and sampling at C+35 visit. Spearman rank test. Volunteers not successfully infected are highlighted in
red. GIA expected to be <20% in malaria-naïve individuals (dotted line). C−1 = baseline pre-CHMI. C+35 = 35 days post-CHMI. ****p <0.0001.
subject with the highest GIA at C−1, in fact the only detectable
response above background, volunteer 150 (46%) had DefExp to
malaria and a PMR at the low end of the distribution seen across
all the volunteers (5.2/48 h) (Figure S2). When all volunteers
were included in the analysis, no correlation was seen between
GIA and PMR or days between start of anti-malarial therapy and
C+35 sampling (Figures 4C,D). However, the same anti-malarial
therapy was used in both KCS and VAC049, and it is likely that
GIAmeasured at C+35 in KCS was influenced to some degree by
Atovaquone/Proguanil and so these results must be treated with
caution.
Analyses of ADRB Activity
In VAC049, no significant increase in ADRB activity was
seen post-CHMI in infected volunteers (Figure 5A). Analysis
of ADRB activity pre- and post-CHMI in KCS showed a
significant increase post-infection (p ≤ 0.0001) (Figure 5B). A
significant difference in ADRB activity was seen betweenMinExp
and DefExp subjects at both C−1 and C+35 (Figure 5C),
consistent with the expected prior exposure status of these
groups. Volunteer 110 had the highest ADRB at C−1, however,
at 0.44 Indexed RLU this was considerably lower than the hyper-
immune serum used as the positive control in the assay. Notably,
this level of ADRB was maintained in this volunteer post-CHMI,
and similar or higher levels were observed in roughly half of the
volunteers in the DefExp group, also consistent with the observed
increase in anti-malarial antibodies seen in the ELISA data
(Figure 2). However, no overall correlation was seen between
PMR and ADRB activity (Figure 5D). The ADRB assay at C−1
did not correlate with GIA, as has been reported recently in
another study (Murungi et al., 2016).
DISCUSSION
We describe detailed serological and functional immunological
responses for Kenyan and UK participants before and after
CHMI with PfSPZ Challenge. This work is the first to compare
immunological responses to a single episode of P. falciparum
infection between malaria-naïve and exposed individuals and
the first to allow correlation of these results with a measure of
NAI—parasite multiplication rate in vivo.
Analysis of antibody responses to key blood-stage antigens
revealed important information both about the malaria exposure
of KCS volunteers and degree of exposure required for
seroconversion. A single malaria infection was capable of
inducing a significant increase in antibody responses against
MSP119, and AMA1 but not RH5 in malaria-naïve adults in
VAC049, with response levels similar to those reported following
mosquito-bite CHMI (Biswas et al., 2014). Of interest there
was a significant difference in C+35 antibody responses to
MSP119, with a similar trend for AMA1, between VAC049
volunteers and MinExp subjects in KCS. These data support
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FIGURE 4 | KCS GIA. (A) Pre- and post-CHMI. (B) MinExp and DefExp volunteers. (C) Correlation between GIA at C−1 and PMR. (D) Correlation between GIA at
C+35 and days between start of anti-malaria therapy and sampling at C+35 visit. Data for volunteer 110 is highlighted in red. Individual and median values are
indicated. Wilcoxon matched-pairs signed rank or Mann Whitney U tests as appropriate. Spearman rank test for correlations. MinExp, minimal prior exposure to
malaria; DefExp, definite prior exposure to malaria. C−1 = baseline pre-CHMI. C+35 = 35 days post-CHMI. ***p < 0.001, ****p < 0.0001.
the presence of some pre-existing immunity to the AMA1
and MSP119 antigens in this group of Kenyan adults, leading
to stronger recall responses post-CHMI, likely attributable to
memory B cell (mBC) responses induced by prior infections.
Indeed, we have previously shown that a single CHMI exposure
is sufficient to induce detectable levels of mBC against MSP119
in UK adults (Elias et al., 2014), whilst mBC responses to both
antigens are well maintained in Kenyan children who have
experienced minimal prior exposure (Ndungu et al., 2012). For
DefExp volunteers in KCS, only antibody responses at C+35 to
MSP119 and AMA1 were of a similar order to that reported for
hyperimmune individuals (Biswas et al., 2014), supporting the
suggestion that DefExp subjects in KCS likely had only mild to
moderate prior exposure to malaria. In the KCS cohort, antibody
responses to AMA1, and schizont at C−1 correlated with PMR,
supporting published data showing a correlation between anti-
AMA1 antibodies and risk of developing severe malaria in
Kenyan children (Murungi et al., 2016), as well as the general
notion that NAI is associated with an increasing magnitude and
repertoire of anti-malarial antibody responses (Murungi et al.,
2013; Rono et al., 2013) likely measured by schizont ELISA.
Development of a functional assay that could reliably predict
NAI would have important applications, however validating
candidate assays is extremely difficult. GIA and ADRB have
both been suggested as candidate measures of NAI, however
supporting evidence is limited (Joos et al., 2010; Duncan et al.,
2012; Llewellyn et al., 2015). Although only one individual in
KCS was qPCR positive but undiagnosed by C+21, analysis of
PMRs showed a spread of values, allowing correlation of PMR
with candidate in vitro assays.
In our study, the GIA assay measured the ability of purified
IgG at 10mg/mL to inhibit the growth of 3D7 clone blood-stage
parasites in vitro over one life cycle. We used this clone as it is
a genetic clone of the parental NF54 strain used for the PfSPZ
Challenge. Volunteer 110 had undetectable GIA prior to CHMI
and yet was able to control parasite growth in vivo. In contrast,
subject 150 who had 46% GIA at C−1, was unable to control
parasite growth to the same degree and was diagnosed with
malaria following CHMI. These findings are in agreement with
those of a recently published AMA1 vaccine study where despite
induction of a median of 59.5% GIA (range 38.5–86.5%) using
10 mg/mL purified IgG (approximately the physiological level),
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FIGURE 5 | VAC049 and KCS ADRB activity. (A) VAC049 all infected volunteers pre- and post-CHMI. (B) KCS all volunteers pre- and post-CHMI. (C) KCS MinExp
and DefExp volunteers. (D) KCS correlation between ADRB activity at C−1 and parasite multiplication rate (PMR). Data for volunteer 110 is highlighted in red.
Individual and median values are indicated. RLU, relative light units. Wilcoxon matched-pairs signed rank or Mann Whitney U tests as appropriate. Spearman rank test
for correlation. MinExp, minimal prior exposure to malaria; DefExp, definite prior exposure to malaria. C−1 = baseline pre-CHMI. C+35 = 35 days post-CHMI. **p <
0.005, ***p < 0.001, ****p < 0.0001.
no impact on PMRwas seen following blood-stage CHMI (Payne
et al., 2016). In contrast, non-human primate vaccine studies that
have associated GIA in vitrowith in vivo protection have achieved
much higher levels of GIA, with protected animals showing
>60% GIA when using 2.5 mg/mL IgG (roughly equivalent to
a 1:4 serum dilution) (Singh et al., 2006; Douglas et al., 2015).
These data suggest GIA induced by vaccines would represent a
“non-natural” form of immunity, and such antibody-mediated
protection requires a much higher threshold level than observed
in clinical studies to date. Our results here suggest volunteer 110
was able to control parasite growth by a mechanism that does not
inhibit merozoite invasion as measured by the GIA assay.
The finding of quinine in a UK volunteer’s serum and
the presumed effect of residual Atovaquone/Proguanil on GIA
measurements at the C+35 time-point in VAC049 and KCS
importantly suggest that anti-malarials, previously assumed to
be removed by IgG purification with a Protein G column and
subsequent dialysis, can give falsely high GIA results. Further
work is needed to repeat this finding and investigate methods
to ensure removal of anti-malarial medications from serum
prior to the GIA assay. In the interim, caution should be taken
interpreting GIA results from samples following anti-malarial
therapy or where the use of anti-malarial drugs is unknown,
for example in field studies. Investigators should also consider
screening individuals demonstrating efficacy in CHMI trials for
surreptitious anti-malarial use.
Whilst infected malaria-naïve volunteers in VAC049 failed to
develop ADRB activity following a single malaria infection, both
MinExp and DefExp subjects in KCS had a significant increase
following CHMI, supporting the conclusion that MinExp
volunteers had some degree of prior exposure to malaria. The
increase in ADRB activity following CHMI was more marked
in DefExp volunteers, possibly due to improved B cell memory
or increased antibody levels capable of opsonizing merozoites
in this group. Significant correlations were seen between ADRB
activity at baseline and C+35 and antibody responses to MSP119,
AMA1 and schizont at these time points, further supporting the
suggestion that ADRB activity correlates with exposure.
Whilst no correlation was seen between ADRB activity and
parasitaemia at diagnosis or PMR, volunteer 110 did have the
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highest ADRB activity at baseline, suggesting the relationship
between ADRB activity and NAI warrants further investigation.
Interestingly, another study shows that volunteer 110 had titers
of antibodies to the surface of infected erythrocytes (iRBC) that
exceeded those of the hyperimmune positive control, suggesting
this may be another possible mechanism by which PMR was
controlled (Abdi et al. Manuscript in preparation). Delineating the
overall contributions of anti-merozoite vs. anti-iRBC antibody
responses to NAI (measured here by reduced in vivo PMR), will
be an important focus of future research that should be greatly
facilitated by access to the CHMI model in endemic areas.
Both VAC049 and KCS were pilot studies, with necessarily
limited samples sizes. This, and the fact volunteers in KCS had
onlyminimal tomoderate NAI, meant the study was limited in its
ability to test for associations between NAI and immunological
readouts. That accepted, these findings, from hypothesis driven
analyses, provide interesting results, suggesting that multiple
antibody-dependent mechanisms are likely to contribute to
protective immunity against malaria. In particular, the ADRB
activity assay and antibodies against AMA1 and schizont extract
show promise as measures of prior exposure to malaria and as
possible predictors of control of parasite growth in vivo.
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Figure S1 | Kaplan Meier plots of time to diagnosis in VAC049 and KCS. (A)
VAC049 where median pre-patent period = 13.19 days for 2500 SPZ ID; 17.8
days for 2500 SPZ IM; and 12.72 days for 25,000 SPZ IM. Comparison between
all groups: p = 0.024, Log rank test. (B) KCS where median pre-patient period =
12.2 days for minimally exposed and 12.1 days for definitely exposed. (C)
VAC049 and KCS showing diagnosed volunteers only (i.e., excluding volunteer
110). P-values = log rank tests. Days post-administration of PfSPZ Challenge =
day between injection and diagnosis. ID, intradermal; IM, intramuscular. MinExp,
Volunteers with minimal prior exposure to malaria. DefExp, Definite prior exposure
to malaria. These data have been reported previously (Hodgson et al., 2014) but
are replotted here for completeness.
Figure S2 | Parasite multiplication rates for all volunteers in KCS. 95%
Confidence intervals for each value are indicated. PMR, parasite multiplication rate
(fold change in parasites over 48 h ). Volunteer 110 is highlighted in red. These
data have been reported previously (Hodgson et al., 2014) but are replotted here
for completeness.
Figure S3 | Comparison of Liver to Blood inoculum between volunteers
diagnosed with malaria in KCS and VAC049. LBI, liver to blood
inoculum—total number of parasites released from liver on C+6.5 as modeled
from the qPCR data.
Figure S4 | Serum IgG antibody responses pre- and post-CHMI for
VAC049 and volunteers with minimal prior exposure to malaria in KCS. (A)
VAC049 (n = 14). Responses are shown before (C−1) and after (C+35) CHMI. (B)
Antibody responses at C−1 for VAC049 and volunteers with minimal prior
exposure to malaria (MinExp) in KCS (n = 14). (C) Antibody responses at C+35
for VAC049 and MinExp volunteers from KCS. Median and individual values are
indicated. Comparisons were performed using Wilcoxon matched-pairs signed
rank or Mann Whitney U tests as appropriate. It should be noted that each ELISA
assay reports antibody responses in arbitrary units, and the magnitude of these
cannot be compared between antigens. ∗∗p < 0.005, ∗∗∗p < 0.001.
Table S1 | Analysis of antibody responses, GIA and ADRB activity for
VAC049: Only subjects infected in VAC049 were included (n = 14). GIA was
not available for VAC049 volunteer 1224 at C−1. ELISA responses for RH5 were
not included in the table as most values were negative. Correlations were
performed using Spearman rank test. Comparisons were performed using
Wilcoxon matched-pairs signed rank or Mann Whitney U tests as appropriate.
∗GIA data not reliable due to likely persistence of anti-malarial drug.
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